Mutation of MET D1228N as an Acquired Potential Mechanism of Crizotinib Resistance in NSCLC with MET Y1003H Mutation

被引：0
|
作者：
Zhu, Jinlian [1 ]
Chen, Jie [1 ]
Liu, Wei [1 ]
Zhang, Junling [2 ]
Gu, Yulan [1 ]
机构：
[1] Nantong Univ, Dept Otolaryngol, Affiliated Changshu Hosp, Changshu, Jiangsu, Peoples R China
[2] 3D Med Inc, Med Dept, Shanghai, Peoples R China
来源：
LUNG CANCER-TARGETS AND THERAPY | 2024年 / 15卷
关键词：
MET Y1003H; MET D1228N; crizotinib; resistance; NSCLC; LUNG; CABOZANTINIB; SENSITIVITY; INHIBITORS; PATIENT; DOMAIN; SITE;
D O I：
10.2147/LCTT.S467584
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Mesenchymal-epithelial transition (MET) gene has been identified as a promising target for treatments. However, different sites of the MET mutation show different effects to MET inhibition. Here, we reported a non-small cell lung cancer (NSCLC) patient harboring MET Y1003H mutation who achieved a durable partial response to crizotinib with a PFS of 22.4 months. Furthermore, we report for the first time the identification of MET D1228N as a possible mechanism of acquired resistance to crizotinib in a patient with MET Y1003H mutation during disease progression.
引用
收藏
页码：123 / 128
页数：6
相关论文
共 36 条
  • [21] Acquired Exon 14 MET Mutation Associated With Resistance to Alectinib in a Patient With ALK- Rearranged NSCLC
    Daniel, Catherine
    Callens, Celine
    Melaabi, Samia
    Bieche, Ivan
    Girard, Nicolas
    JTO CLINICAL AND RESEARCH REPORTS, 2020, 1 (04):
  • [22] Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer
    Piper-Vallillo, Andrew J.
    Halbert, Brian T.
    Rangachari, Deepa
    Kobayashi, Susumu S.
    Costa, Daniel B.
    JTO CLINICAL AND RESEARCH REPORTS, 2020, 1 (04):
  • [23] Case Report: Sequential Combination Targeted Therapy With Type I and II MET Inhibitors in a Metastatic EGFR-Mutated, MET-Amplified NSCLC Patient With Acquired MET Y1230H Mutation
    Cai, Boning
    Li, Xiaomo
    Huang, Xiang
    Ma, Tonghui
    Qu, Baolin
    Yu, Wei
    Yang, Wei
    Zhang, Pei
    Chen, Jing
    Liu, Fang
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [24] A case study: OncoRat is a viable patient avatar for a NSCLC patient with a Y1248H Met activating mutation
    Noto, Fallon K.
    Adedeji, Bisoye Towobola
    Moody, Sam
    Brenzel, Chris
    Crawford, Jack
    Narla, Goutham
    Jamling, Tseten Yeshi
    CANCER RESEARCH, 2019, 79 (13)
  • [25] Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer
    Li, Anna
    Yang, Jin-ji
    Zhang, Xu-chao
    Zhang, Zhou
    Su, Jian
    Gou, Lan-ying
    Bai, Yu
    Zhou, Qing
    Yang, Zhenfan
    Han Han-Zhang
    Zhong, Wen-Zhao
    Chuai, Shannon
    Zhang, Qi
    Xie, Zhi
    Gao, Hongfei
    Chen, Huajun
    Wang, Zhen
    Wang, Zheng
    Yang, Xue-ning
    Wang, Bin-chao
    Gan, Bin
    Chen, Zhi-hong
    Jiang, Ben-yuan
    Wu, Si-pei
    Liu, Si-yang
    Xu, Chong-rui
    Wu, Yi-long
    CLINICAL CANCER RESEARCH, 2017, 23 (16) : 4929 - 4937
  • [26] Osimertinib and Capmatinib Combination Therapy to Overcome MET Y1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report
    Wilgucki, Molly
    Yeung, Vincent
    Ho, Grace
    Montenegro, Gabriela L. Bravo
    Jones, Greg
    Reuss, Joshua E.
    V. Liu, Stephen
    Kim, Chul
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (10):
  • [27] ALKG1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor
    Michels, Sebastian Y. F.
    Scheel, Andreas H.
    Wuendisch, Thomas
    Heuckmann, Johannes M.
    Menon, Roopika
    Puesken, Michael
    Kobe, Carsten
    Pasternack, Helen
    Heydt, Carina
    Scheffler, Matthias
    Fischer, Rieke
    Schultheis, Anne M.
    Merkelbach-Bruse, Sabine
    Heukamp, Lukas
    Buettner, Reinhard
    Woelf, Jurgen
    NPJ PRECISION ONCOLOGY, 2017, 1
  • [28] ALKG1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor
    Sebastian Y. F. Michels
    Andreas H. Scheel
    Thomas Wündisch
    Johannes M. Heuckmann
    Roopika Menon
    Michael Puesken
    Carsten Kobe
    Helen Pasternack
    Carina Heydt
    Matthias Scheffler
    Rieke Fischer
    Anne M. Schultheis
    Sabine Merkelbach-Bruse
    Lukas Heukamp
    Reinhard Büttner
    Jürgen Wolf
    npj Precision Oncology, 1
  • [29] Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC
    Minari, Roberta
    Bordi, Paola
    La Monica, Silvia
    Squadrilli, Anna
    Leonetti, Alessandro
    Bottarelli, Lorena
    Azzoni, Cinzia
    Lagrasta, Costanza Anna Maria
    Gnetti, Letizia
    Campanini, Nicoletta
    Petronini, Pier Giorgio
    Alfieri, Roberta
    Tiseo, Marcello
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (06) : E89 - E91
  • [30] A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib
    Mahjoubi, Linda
    Gazzah, Anas
    Besse, Benjamin
    Lacroix, Ludovic
    Soria, Jean-Charles
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (03) : 397 - 398
1234